Social determinants of health (SDOH) are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.
Watson, a professor of Medicine/Cardiology at the David Geffen School of Medicine at UCLA, began with data that has helped drive the conversation about SDOH across medical specialties: the outsized effect on mortality that the COVID-19 pandemic had on people of color.
“Just as the rich seem to get richer, and the poor seem to get poorer, that was the same with life expectancy lost during the pandemic.”
In 2018, she said, overall life expectancy in males was 78.8 years, although there were disparities by race. By 2020, at the peak of the pandemic, the overall life expectancy for males had dropped to 75.1 years—but for Black males, it fell to 68.3.
“That is 3 years after you hit Medicare age—that is probably around the time you’re having your first grandchild,” Watson said. “That is shocking and unacceptable.”
These racial differences in outcomes occur, she said, even though genetically, the difference between the races is barely detectable—there’s only about 0.1% difference in DNA.
“Race is social construct, not based on biology or genetics,” Watson said. Rather, “Race refers to a group of people who typically share some physical characteristics.” Ethnicity refers to a group of people who share a culture; Watson said race refers to how people look, while ethnicity refers to how people live.
And yet, because of racism, many characteristics related to life expectancy segregate along racial lines. “So, it’s not an entirely useless social construct,” Watson said.
She highlighted the influence of the Swedish botanist Carl Linnaeus, called the “father of modern taxonomy” for his work categorizing plants, animals, and later, humans. Except, his descriptions of the various races was quite racist. White people, Watson explained, were “gentle and inventive,” while Black people were “impassive and lazy.”
“This is where we get our races,” she said. “It started out with racism.”
With Wendy Post, MD, MS, of Johns Hopkins as first author, Watson just published results in Circulation that show Black participants in the MESA study had a 34% higher hazard from all-cause and cardiovascular disease mortality. “Clearly, we see differences in life expectancy.”
In that study, she and Post controlled for SDOH factors, which eliminated some of the differences, but not all.
Watson has seen the effects up close. She described patient who had just been discharged after an uncomplicated STEMI. He was given dietary advice; doctors made sure he was given generic prescriptions, and he was signed up for cardio rehabilitation. But at the patient’s next appointment, he reported having a tough time affording the medications, which were $5 to $8 a month. And because he had 2 jobs, including 1 on the weekends, he was missing the rehab visits.
She described the frustration of seeing patients come to clinic with McDonald’s bags. “None of us like to see this.” But a patient told her that’s the breakfast he could afford, and the Wi-Fi is free.
“We have to understand that the social determinants account more than so many other things for many of our patients,” Watson said.
There are many modifiable factors that influence health, but income trumps so many others. She pointed to the famous Whitehall study of British civil servants, which compared mortality among social classes. The hypothesis that high-ranking executives would have worse mortality turned out to be completely wrong; the lowest-ranking workers fared worst.
“The impact of social advantage on health is substantial,” she said. There is a 14-year difference in cardiovascular mortality in different regions of the country based on socioeconomic differences.
And as hard as it is to measure, “We can’t forget racism.”
Overly racist acts are easy to recognize, she said. But unconscious bias is not—and structural racism is “almost invisible.”
Social determinants of health, she said, start at birth and exist as people grow, work and age, and must be accounted for. “Health differences are health differences,” Watson said. “Health inequities are those that are unjust and unfair.”
Social Determinants, Including Racism, Are Major Drivers of Health Inequity, Watson Says
Social determinants of health are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.
Social determinants of health (SDOH) are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.
Watson, a professor of Medicine/Cardiology at the David Geffen School of Medicine at UCLA, began with data that has helped drive the conversation about SDOH across medical specialties: the outsized effect on mortality that the COVID-19 pandemic had on people of color.
“Just as the rich seem to get richer, and the poor seem to get poorer, that was the same with life expectancy lost during the pandemic.”
In 2018, she said, overall life expectancy in males was 78.8 years, although there were disparities by race. By 2020, at the peak of the pandemic, the overall life expectancy for males had dropped to 75.1 years—but for Black males, it fell to 68.3.
“That is 3 years after you hit Medicare age—that is probably around the time you’re having your first grandchild,” Watson said. “That is shocking and unacceptable.”
These racial differences in outcomes occur, she said, even though genetically, the difference between the races is barely detectable—there’s only about 0.1% difference in DNA.
“Race is social construct, not based on biology or genetics,” Watson said. Rather, “Race refers to a group of people who typically share some physical characteristics.” Ethnicity refers to a group of people who share a culture; Watson said race refers to how people look, while ethnicity refers to how people live.
And yet, because of racism, many characteristics related to life expectancy segregate along racial lines. “So, it’s not an entirely useless social construct,” Watson said.
She highlighted the influence of the Swedish botanist Carl Linnaeus, called the “father of modern taxonomy” for his work categorizing plants, animals, and later, humans. Except, his descriptions of the various races was quite racist. White people, Watson explained, were “gentle and inventive,” while Black people were “impassive and lazy.”
“This is where we get our races,” she said. “It started out with racism.”
With Wendy Post, MD, MS, of Johns Hopkins as first author, Watson just published results in Circulation that show Black participants in the MESA study had a 34% higher hazard from all-cause and cardiovascular disease mortality. “Clearly, we see differences in life expectancy.”
In that study, she and Post controlled for SDOH factors, which eliminated some of the differences, but not all.
Watson has seen the effects up close. She described patient who had just been discharged after an uncomplicated STEMI. He was given dietary advice; doctors made sure he was given generic prescriptions, and he was signed up for cardio rehabilitation. But at the patient’s next appointment, he reported having a tough time affording the medications, which were $5 to $8 a month. And because he had 2 jobs, including 1 on the weekends, he was missing the rehab visits.
She described the frustration of seeing patients come to clinic with McDonald’s bags. “None of us like to see this.” But a patient told her that’s the breakfast he could afford, and the Wi-Fi is free.
“We have to understand that the social determinants account more than so many other things for many of our patients,” Watson said.
There are many modifiable factors that influence health, but income trumps so many others. She pointed to the famous Whitehall study of British civil servants, which compared mortality among social classes. The hypothesis that high-ranking executives would have worse mortality turned out to be completely wrong; the lowest-ranking workers fared worst.
“The impact of social advantage on health is substantial,” she said. There is a 14-year difference in cardiovascular mortality in different regions of the country based on socioeconomic differences.
And as hard as it is to measure, “We can’t forget racism.”
Overly racist acts are easy to recognize, she said. But unconscious bias is not—and structural racism is “almost invisible.”
Social determinants of health, she said, start at birth and exist as people grow, work and age, and must be accounted for. “Health differences are health differences,” Watson said. “Health inequities are those that are unjust and unfair.”
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Climate Change, Pollution’s Growing Impact on Dermatology
March 10th 2025Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their actions may inspire others to follow suit.
Read More
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Climate Change, Pollution’s Growing Impact on Dermatology
March 10th 2025Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their actions may inspire others to follow suit.
Read More
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More